APA

Horenstein R. B., Madabushi R., Zineh I., Yerges-Armstrong L. M., Peer C. J., Schuck R. N., Figg W. D., Shuldiner A. R. & Pacanowski M. A. (20150409). Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. : Journal of clinical pharmacology.

Chicago

Horenstein Richard B, Madabushi Rajnikanth, Zineh Issam, Yerges-Armstrong Laura M, Peer Cody J, Schuck Robert N, Figg William Douglas, Shuldiner Alan R and Pacanowski Michael A. 20150409. Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. : Journal of clinical pharmacology.

Harvard

Horenstein R. B., Madabushi R., Zineh I., Yerges-Armstrong L. M., Peer C. J., Schuck R. N., Figg W. D., Shuldiner A. R. and Pacanowski M. A. (20150409). Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. : Journal of clinical pharmacology.

MLA

Horenstein Richard B, Madabushi Rajnikanth, Zineh Issam, Yerges-Armstrong Laura M, Peer Cody J, Schuck Robert N, Figg William Douglas, Shuldiner Alan R and Pacanowski Michael A. Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. : Journal of clinical pharmacology. 20150409.